Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Buy" from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) has earned an average rating of "Buy" from the five analysts that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year is $10.80.

A number of research firms recently weighed in on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com downgraded Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Finally, Barclays lifted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday.

Insider Transactions at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 62,590 shares of the firm's stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total value of $501,345.90. Following the transaction, the director now owns 1,968,886 shares in the company, valued at approximately $15,770,776.86. This trade represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 160,000 shares of company stock worth $1,292,000. Company insiders own 26.56% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMRX. Chartwell Investment Partners LLC lifted its stake in shares of Amneal Pharmaceuticals by 21.3% in the third quarter. Chartwell Investment Partners LLC now owns 82,410 shares of the company's stock worth $686,000 after acquiring an additional 14,477 shares during the period. Versor Investments LP increased its holdings in shares of Amneal Pharmaceuticals by 191.3% during the third quarter. Versor Investments LP now owns 40,200 shares of the company's stock valued at $334,000 after acquiring an additional 26,400 shares in the last quarter. Aigen Investment Management LP acquired a new position in Amneal Pharmaceuticals during the third quarter worth $213,000. Victory Capital Management Inc. raised its stake in shares of Amneal Pharmaceuticals by 58.7% in the third quarter. Victory Capital Management Inc. now owns 99,215 shares of the company's stock worth $825,000 after purchasing an additional 36,700 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in Amneal Pharmaceuticals during the 3rd quarter valued at $37,000. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX traded up $0.09 on Friday, hitting $8.76. 2,651,338 shares of the company were exchanged, compared to its average volume of 1,352,426. The company's 50 day moving average price is $8.10 and its 200-day moving average price is $8.32. Amneal Pharmaceuticals has a twelve month low of $5.18 and a twelve month high of $9.48. The firm has a market capitalization of $2.71 billion, a P/E ratio of -12.88 and a beta of 1.10.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. As a group, equities analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.